A Cost Per Responder Analysis of Secukinumab Vs Adalimumab Based on A Matching-Adjusted Indirect Comparison for the Treatment of Ankylosing Spondylitis from A German Payer Perspective
Value in health（2016）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined